[go: up one dir, main page]

MA30654B1 - Therapie tumorale avec anticorps anti-vegf - Google Patents

Therapie tumorale avec anticorps anti-vegf

Info

Publication number
MA30654B1
MA30654B1 MA31650A MA31650A MA30654B1 MA 30654 B1 MA30654 B1 MA 30654B1 MA 31650 A MA31650 A MA 31650A MA 31650 A MA31650 A MA 31650A MA 30654 B1 MA30654 B1 MA 30654B1
Authority
MA
Morocco
Prior art keywords
tumor therapy
vegf antibodies
relates
her2
vegf
Prior art date
Application number
MA31650A
Other languages
English (en)
Inventor
Thomas Friess
Max Hasmann
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30654(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30654B1 publication Critical patent/MA30654B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention concerne un procédé de traitement d'un patient souffrant d'une rechute d'un cancer positif à HER2, avec un anticorps anti-VEGF pendant ou après un traitement avec un anticorps anti-HER2. L'invention concerne également des articles manufacturés correspondants.
MA31650A 2006-08-21 2009-02-19 Therapie tumorale avec anticorps anti-vegf MA30654B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06017330 2006-08-21

Publications (1)

Publication Number Publication Date
MA30654B1 true MA30654B1 (fr) 2009-08-03

Family

ID=37607207

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31650A MA30654B1 (fr) 2006-08-21 2009-02-19 Therapie tumorale avec anticorps anti-vegf

Country Status (28)

Country Link
US (6) US20080050385A1 (fr)
EP (2) EP2441472B1 (fr)
JP (3) JP2010501498A (fr)
KR (1) KR101136763B1 (fr)
CN (1) CN101505792B (fr)
AR (1) AR062419A1 (fr)
AU (1) AU2007287794B2 (fr)
BR (1) BRPI0715829A2 (fr)
CA (1) CA2660681A1 (fr)
CL (1) CL2007002404A1 (fr)
CO (1) CO6150193A2 (fr)
CR (1) CR10590A (fr)
DK (1) DK2056874T3 (fr)
ES (2) ES2392630T3 (fr)
IL (2) IL196810A0 (fr)
MA (1) MA30654B1 (fr)
MX (1) MX2009001715A (fr)
MY (1) MY150756A (fr)
NO (1) NO20090450L (fr)
NZ (1) NZ574580A (fr)
PE (1) PE20080911A1 (fr)
PL (1) PL2056874T3 (fr)
RU (1) RU2528884C2 (fr)
SG (1) SG174090A1 (fr)
SI (1) SI2056874T1 (fr)
TW (2) TW201107346A (fr)
WO (1) WO2008022746A1 (fr)
ZA (1) ZA200901200B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1282443T1 (sl) 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
KR20150043558A (ko) * 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (fr) * 2004-12-07 2006-06-15 Genentech, Inc. Selection de patients pour une therapie avec un inhibiteur de her
RU2438705C2 (ru) 2005-01-21 2012-01-10 Дженентек, Инк. Введение фиксированных доз her-антител
CA2596133C (fr) 2005-02-23 2016-11-15 Genentech, Inc. Retardement de la progression de la maladie ou survie des patients atteints du cancer
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
ES2392630T3 (es) * 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP6320753B2 (ja) 2010-05-27 2018-05-09 ゲンマブ エー／エス Ｈｅｒ２に対するモノクローナル抗体
WO2011147982A2 (fr) 2010-05-27 2011-12-01 Genmab A/S Anticorps monoclonaux contre l'épitope de her2
AU2011281700B2 (en) * 2010-07-19 2017-02-09 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
BR112013004012B1 (pt) * 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
AU2012348600A1 (en) * 2011-12-05 2014-05-22 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2013148159A1 (fr) * 2012-03-30 2013-10-03 Fibrogen Inc Procédés thérapeutiques pour une carcinomatose péritonéale
CA2907776C (fr) 2013-04-16 2020-04-14 Genentech, Inc. Variantes de pertuzumab et leur evaluation
AU2015249633B2 (en) 2014-04-25 2020-10-15 Genentech, Inc. Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
DK3302551T3 (da) 2015-05-30 2024-08-26 Hoffmann La Roche Fremgangsmåder til behandling af HER2-positiv tidligere ubehandlet metastatisk brystkræft
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TW202140776A (zh) 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
EP3868404A1 (fr) 2017-01-17 2021-08-25 F. Hoffmann-La Roche AG Formulations sous-cutanées d'anticorps her2
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
CA3059241A1 (fr) 2017-04-24 2018-11-01 Genentech, Inc. Mutations erbb2/her2 dans le domaine transmembranaire ou juxtamembranaire
WO2022005499A1 (fr) 2020-06-29 2022-01-06 Genentech, Inc. Association à dose fixe de pertuzumab et de trastuzumab
WO2022051721A1 (fr) * 2020-09-04 2022-03-10 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions et méthodes de combinaison pour traiter le cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
CA2259222A1 (fr) 1996-06-27 1997-12-31 Pfizer Inc. Derives de 2-(2-oxo-ethylidene)-imidazolidin-4-one et leur utilisation comme inhibiteurs de la farnesyl-proteine-transferase
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ATE501170T1 (de) 1997-04-07 2011-03-15 Genentech Inc Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
CA2332331A1 (fr) 1998-05-15 1999-11-25 Francisco Robert Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
KR20010072991A (ko) 1998-08-27 2001-07-31 실버스타인 아써 에이. 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (fr) 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
SK11002001A3 (sk) 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
PT1189634E (pt) 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
SI2283867T1 (sl) 1999-06-25 2014-07-31 Immunogen, Inc. Metode zdravljenja z majtanzinoidom konjugiranim protitelesom anti-ErbB
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DK1106612T3 (da) 1999-11-30 2004-05-17 Pfizer Prod Inc Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2003042402A2 (fr) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
AU2003222252A1 (en) 2002-03-12 2003-09-29 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
WO2003087131A2 (fr) 2002-04-10 2003-10-23 Genentech, Inc Variants d'anticorps anti-her2
WO2005000900A1 (fr) 2003-05-30 2005-01-06 Genentech, Inc. Traitement au moyen d'anticorps anti-vegf
WO2005000090A2 (fr) 2003-05-30 2005-01-06 Medi-Screw, Inc. Systemes d'implants medicaux
KR20060069825A (ko) 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DK1718677T3 (da) 2003-12-19 2012-07-09 Genentech Inc Monovalente antistoffragmenter egnede som terapeutiske midler
JP2008511337A (ja) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
WO2006042173A2 (fr) * 2004-10-04 2006-04-20 Genentech, Inc. Modulateurs d'activateur du facteur de croissance des hepatocytes
BRPI0611766A2 (pt) * 2005-06-08 2011-12-20 Dana Farber Cancer Institute métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
ES2392630T3 (es) * 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Also Published As

Publication number Publication date
AR062419A1 (es) 2008-11-05
US20080050385A1 (en) 2008-02-28
AU2007287794B2 (en) 2013-03-28
KR20090032136A (ko) 2009-03-31
ES2546066T3 (es) 2015-09-18
HK1134441A1 (en) 2010-04-30
CA2660681A1 (fr) 2008-02-28
MX2009001715A (es) 2009-02-25
US20110223159A1 (en) 2011-09-15
JP2010501498A (ja) 2010-01-21
IL238045A0 (en) 2015-05-31
CN101505792B (zh) 2012-10-03
NZ574580A (en) 2011-12-22
KR101136763B1 (ko) 2012-04-24
ES2392630T3 (es) 2012-12-12
CN101505792A (zh) 2009-08-12
US20180251536A1 (en) 2018-09-06
DK2056874T3 (da) 2012-10-15
PL2056874T3 (pl) 2013-02-28
US20150239969A1 (en) 2015-08-27
EP2441472B1 (fr) 2015-06-10
MY150756A (en) 2014-02-28
CR10590A (es) 2009-03-20
SG174090A1 (en) 2011-09-29
WO2008022746A1 (fr) 2008-02-28
US20130183292A1 (en) 2013-07-18
JP2013163687A (ja) 2013-08-22
BRPI0715829A2 (pt) 2013-07-23
JP2015214582A (ja) 2015-12-03
AU2007287794A1 (en) 2008-02-28
NO20090450L (no) 2009-02-27
EP2056874A1 (fr) 2009-05-13
TW201107346A (en) 2011-03-01
SI2056874T1 (sl) 2012-12-31
RU2009110102A (ru) 2010-09-27
CL2007002404A1 (es) 2008-04-18
RU2528884C2 (ru) 2014-09-20
US20100285010A1 (en) 2010-11-11
PE20080911A1 (es) 2008-08-15
EP2056874B1 (fr) 2012-09-19
ZA200901200B (en) 2013-08-28
CO6150193A2 (es) 2010-04-20
IL196810A0 (en) 2011-08-01
TW200825106A (en) 2008-06-16
EP2441472A1 (fr) 2012-04-18

Similar Documents

Publication Publication Date Title
MA30654B1 (fr) Therapie tumorale avec anticorps anti-vegf
DK1210115T3 (da) Doseringer til behandling med anti-ErB2-antistoffer
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2004008099A8 (fr) Procedes d'identification de tumeurs sensibles a un traitement par anticorps anti-erbb2
DE602006013029D1 (de) Anti-egfr-antikörper
ATE540696T1 (de) Erbb2-antagonisten für die tumorschmerztherapie
MA30348B1 (fr) Diagnostics et traitements de tumeurs
DK1385864T3 (da) Anti-VEGF-2-antistoffer
UA87804C2 (ru) Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir)
MA40913A (fr) Conjugués anticorps-médicament
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
EA200870141A1 (ru) Комбинационная терапия с использованием антител к egfr и her2
WO2007135546A3 (fr) TRAITEMENT DU CANCER PAR DES ANTICORPS ANTI-IL-1α
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
WO2004043239A3 (fr) Antigene pipa et anticorps de liaison a celui-ci
WO2024062072A3 (fr) Anticorps monoclonaux anti-ccr8 et leur usage thérapeutique
PL1684770T3 (pl) Oligo-beta-(1,3)-glukan i przeciwrakowe przeciwciała monoklonalne
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
WO2006078853A3 (fr) Proteine d'interaction avec la thioredoxine (txnip) en tant que regulateur de la fonction vasculaire
MX2025003314A (es) Anticuerpos monoclonales anti-ccr8 y su uso terapeutico
UA98756C2 (ru) Антитело, которое связывается с cd38, для лечения заболевания, опосредованного cd38
UA102085C2 (ru) ВЫДЕЛЕННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С hGM-CSF, И КОМПОЗИЦИЯ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ
UA93875C2 (ru) Выделенное химерическое или гуманизированное антитело, kotopoe специфически связывается c полипептидом tat10772 (ca125)